Abstract
Immunoglobulin replacement can be life-saving for certain individuals with immunodeficiencies. Several options for IgG replacement exist, including preparations of both intravenous (IVIG) and subcutaneous IgG (SCIG) replacement. SCIG administration is an increasingly used method of replacement with potential advantages including fewer systemic side effects, no need for IV access, patient-reported improved quality of life, and decreased cost. In addition, patients with associated co-morbidities, for instance, those that cause protein loss, may demonstrate more stable, consistent IgG levels on subcutaneous replacement when compared to intravenous replacement.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
